Model Informed preciSion doSIng tO iNdividualise and Optimize Pharmacotherapeutic Treatment

NCT06095895 — Completed, 29 participants, Radboud University Medical Center

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  
RegistryNCT06095895, acronym MISSION
StatusCompleted
Study typeObservational
Enrollment29 (Actual)
SponsorRadboud University Medical Center (Other)
ConditionsPharmacokinetics, Area Under Curve, Tacrolimus, Immunosuppressive Agents, Mycophenolic Acid
Interventionsvenipuncture (Other)
Datesstart 2024-03-15, primary completion 2024-11-15, completion 2025-11-20, first posted 2023-10-23, last updated 2025-12-02
Locations1 site in Netherlands

Related Papers Related Patents Related Grants Related Experts
All trials for Pharmacokinetics All trials for Area Under Curve All trials of venipuncture

-Summary

This is a prospective observational study of MIPD in clinical practice for paediatric kidney transplant patients using tacrolimus and mycophenolic acid in Radboudumc. Dose individualization in paediatric kidney transplant patients using the InsightRX platform is performed as standard care, meaning that a pharmacokinetic model and drug levels measured at t=0, t=1 and t=2 hours will be used to calculate the exposure. Based on the estimated exposure, the pharmacist gives a dose recommendation to the physician, who can then modify the dosage of mycophenolic acid or tacrolimus. The selected dose and the measured MPA and tacrolimus concentrations will be used to predict the future exposure. A second exposure measurement will be performed to evaluate whether our model is able to predict future exposure.

Expand all sections  ·  Collapse all

+Arms and interventions

  • venipuncture (Other): An additional measurement of exposure of mycophenolic acid and/or tacrolimus will be performed

+Outcome measures

Primary outcomes

  • Bias [1 year]: Mean prediction error
  • Precision [1 year]: Root mean squared error

+Eligibility

Sex: All, ages: 0 Years to 18 Years

Inclusion Criteria:

* Kidney transplant patients using tacrolimus and/or mycophenolic acid
* Age between 0 and 18 years
* Indication for an AUC measurement - judgement of clinician

Exclusion Criteria:

* Incapacitated patients
* No informed consent
* Not proficient in the Dutch language

+Locations (1)

FacilityCityCountryStatus
RadboudumcNijmegen, GelderlandNetherlands

+Publications

  • Results publication: Heida A, Cornelissen EAM, Aarnoutse RE, de Winter BCM, Keizer RJ, Ter Heine R, Jager NGL. Structured Evaluation of Model-Informed Precision Dosing of Mycophenolic Acid and Tacrolimus in Pediatric Patients with Kidney Disease. Clin Pharmacokinet. 2026 Sep 30. doi: 10.1007/s40262-026-01708-3. Online ahead of print. PMID 42814375

+Investigators